Isomorphic Labs' Drug Design Engine expands capabilities beyond AlphaFold

Isomorphic Labs, an AI-driven biotech firm, has launched a new drug design engine. The engine is aimed at accelerating therapeutic molecule discovery. It builds on the breakthroughs of AlphaFold's protein folding predictions. Developers claim it unlocks capabilities that AlphaFold alone cannot provide. The platform integrates structural insights with chemical design tools. By extending beyond pure structure prediction, it may shorten development timelines. Reduced costs and faster iterations are expected benefits for pharma companies. Industry observers will watch how the engine influences future drug pipelines.